Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

NCT05665348 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

229

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma
Metastatic Cancer
Metastatic Tumor

Interventions

DRUG: Ipilimumab Injection
DRUG: Atezolizumab Injection
DRUG: Bevacizumab

Sponsor

Federation Francophone de Cancerologie Digestive